ELVN

Enliven TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$58.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$38.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Current sentiment looks cautious rather than outright bullish. The March 3, 2026 primary-source update gave investors a credible 2026 milestone map and a long runway, but the evidence set is still dominated by company-guided clinical milestones rather than external validation or broadened coverage [#PR-2026-03-03] [#8-K-2026-03-03] [#10-K-2026-03-03]. With deterministic signals negative and catalyst density modest, this reads more like a monitoring setup around upcoming ELVN-001 execution than a high-conviction upside call.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventAdditional Phase 1 ENABLE data mid-2026High impact

Management guided to a mid-year presentation of additional Phase 1 data from the ongoing ENABLE trial for ELVN-001; that dataset is the next concrete de-risking checkpoint after the initial Phase 1b update, with timing inferred from the company’s 'mid-year' language [#PR-2026-03-03].

2026-09-30eventFDA alignment on dose selection and Phase 3 designHigh impact

Enliven said 2026 should include regulatory alignment with the FDA on dose selection and Phase 3 trial design for ELVN-001; that interaction matters because the company is still converting promising early data into a registrational path, with date inferred from 2026 company guidance [#PR-2026-03-03] [#10-K-2026-03-03].

2026-11-15catalystENABLE-2 Phase 3 initiation in second half of 2026High impact

The company plans to initiate ENABLE-2, a 2L+ Phase 3 pivotal trial of ELVN-001, in the second half of 2026; successful start would be the clearest proof that ELVN-001 is moving into late-stage development, but delay would likely pressure sentiment, with date inferred from 'second half of 2026' guidance [#PR-2026-03-03] [#10-K-2026-03-03].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology